- IRS official refuses to answer questions at scandal hearing |
- Global stocks, oil fall after Bernanke; dollar gains |
- Oklahoma tornado victims astounded at how they survived |
- CORRECTED-White House threatens veto of bill to bypass Obama on Keystone
- Man linked to Boston bombing suspect killed by FBI in Florida
Zogenix to Present at the 24th Annual Piper Jaffray Healthcare Conference
SAN DIEGO, Nov. 15, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Roger L. Hawley, Chief Executive Officer, and Ann Rhoads, Executive Vice President and Chief Financial Officer, will be presenting at the 24th Annual Piper Jaffray Healthcare Conference on November 28, 2012 in New York City.
Event: 24th Annual Piper Jaffray Healthcare Conference
Date: Wednesday, November 28, 2012
Place: New York City
Time: 1:00 pm ET
The fireside chat style presentation will be webcast live and archived for 30 days on Zogenix' Investor Relations website at ir.zogenix.com. Mr. Hawley and Ms. Rhoads will also be available to participate in one-on-one meetings at the conference.
Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.
For additional information, please visit www.zogenix.com.
CONTACT: INVESTORS: Zack Kubow | The Ruth Group 646.536.7020 | email@example.com MEDIA: Tracy Lessor | The Ruth Group 646.536.7006 | firstname.lastname@example.org